Anti-IL2 Antibody (PE), Mouse Monoclonal

1/1
Price:
Size:
Number:

Anti-IL2 Antibody (PE), Mouse Monoclonal General Information

Product name
Anti-IL2 Antibody (PE), Mouse Monoclonal
Validated applications
FCM
Species reactivity
Reacts with: Human
Specificity
Human IL2
Immunogen
Recombinant Human IL2 Protein (Catalog#11848-HNAE)
Preparation
This antibody was produced from a hybridoma resulting from the fusion of a mouse myeloma with B cells obtained from a mouse immunized with purified, recombinant Human IL2 (rh IL2; Catalog#11848-HNAE; P60568-1; Ala21-Thr153) and conjugated with PE under optimum conditions, the unreacted PE was removed.
Source
Monoclonal Mouse IgG2a Clone #03
Purification
Protein A
Formulation
Aqueous solution containing 0.5% BSA and 0.09% sodium azide
Conjugate
PE
Concentration
5 μl/Test, 0.1 mg/ml
Form
Liquid
Shipping
This antibody is shipped as liquid solution at ambient temperature. Upon receipt, store it immediately at the temperature recommended below.
Storage
This antibody can be stored at 2℃-8℃ for twelve months without detectable loss of activity. Protected from prolonged exposure to light. Do not freeze ! Sodium azide is toxic to cells and should be disposed of properly. Flush with large volumes of water during disposal.

Anti-IL2 Antibody (PE), Mouse Monoclonal Images

Flow cytometric analysis of Human IL2 expression on human peripheral blood lymphocytes. Human peripheral blood mononulcear cells were stimulated for 4-6 hours with PMA and Ionomycin in the presence of GolgiPlug. The cells were treated according to manufacturer’s manual (BD Pharmingen™ Cat. No. 554714), stained with PE-conjugated anti-Human IL2 and FITC-conjugated anti-Human CD3. The dot plots were derived from gated events with the forward and side light-scatter characteristics of viable lymphocytes.

Anti-IL2 Antibody (PE), Mouse Monoclonal: Synonyms

Anti-IL-2 Antibody; Anti-Interleukin-2 Antibody; Anti-lymphokine Antibody; Anti-TCGF Antibody

IL2 Background Information

Interleukin-2, also known as a T-cell growth factor, TCGF, Aldesleukin, and IL2, is a secreted protein that belongs to the IL-2 family. Interleukin-2 / IL-2 was the first interleukin molecule to be discovered. Interleukin-2 / IL-2 molecule was first purified to homogeneity by immunoaffinity chromatography by Kendall Smith and his team at Dartmouth Medical School. Interleukin-2 / IL-2 was also the first cytokine shown to mediate its effects via a specific IL-2 receptor, and it was also the first interleukin to be cloned and expressed from a complementary DNA (cDNA) library. Interleukin-2 / IL-2 was designated number 2 because Smith's data at the time indicated that IL-1, produced by macrophages, facilitates IL-2 production by T lymphocytes (T cells).
Interleukin-2 / IL-2 is produced by T-cells in response to antigenic or mitogenic stimulation, this protein is required for T-cell proliferation and other activities crucial to regulation of the immune response. Interleukin-2 / IL-2 is normally produced by the body during an immune response. When environmental substances (molecules or microbes) gain access to the body, these substances (termed antigens) are recognized as foreign by antigen receptors that are expressed on the surface of lymphocytes. Antigen binding to the T cell receptor (TCR) stimulates the secretion of Interleukin-2 / IL-2 and the expression of IL-2 receptors IL-2R. The IL-2 / IL-2R interaction then stimulates the growth, differentiation, and survival of antigen-selected cytotoxic T cells via the activation of the expression of specific genes. Interleukin-2 / IL-2 can stimulate B-cells, monocytes, lymphokine-activated killer cells, natural killer cells, and glioma cells. The World Reference Standard for Interleukin-2 / IL-2 is produced by the National Institute of Biological Standards and Control in the UK. A recombinant form of Interleukin-2 / IL-2 for clinical use is manufactured by Chiron Corporation with the brand name Proleukin. It has been approved by the Food and Drug Administration (FDA) for the treatment of cancers (malignant melanoma, renal cell cancer), and is in clinical trials for the treatment of chronic viral infections, and as a booster (adjuvant) for vaccines. The use of Interleukin-2 / IL-2 in HIV therapy is ineffective.
Full Name
interleukin 2
Research Areas
Related Pathways
  • Common G-Chain signaling pathway
    Common G-Chain signaling pathway
References
  • Smith KA, et al.,1980,  J. Exp. Med.151 (6): 1551-6. 
  • Smith KA, et al.,1980, Nature. 287 (5785): 853-5.
  • Taniguchi T, et al.,1983, Nature. 302 (5906): 305.
  • Cantrell DA, et al.,1984, Science. 224 (4655): 1312-6. 
  • Smith KA, et al.,1988, Science. 240 (4856): 1169-76.
  • Wang X. et al., 2005, Science 310:1159-63.
  • Stauber D.J. et al., 2006, Proc. Natl. Acad. Sci. USA. 103: 2788-93.

Standard Antibody Development Service

Rabbit MAb

Mouse MAb

Rabbit PAb

Fast Antibody Development Service

Mouse MAb

Rabbit PAb

Add to Cart Successfully Add to Cart Failed Shopping cart is being updated, please wait U.S.A.